Puma Biotechnology Inc.

Acquiring and developing novel therapeutics for the treatment of cancer

Puma Biotechnology is a publicly-traded pharmaceutical company (NASDAQGS: PBYI) founded in September 2010 by Alan Auerbach and headquartered in Los Angeles, CA. The company in-licenses compounds that were already in clinical development. In August 2011 Puma licensed two drug candidates from Pfizer: neratinib (PB272) and an analog (PB357) to serve as a backup candidate. In October 2011 as part of an approximately $60 million financing round, it performed a reverse merger with the shell company, Innovative Acquisitions Corp., which had been formed in 2007. In April 2012 the company's stock began trading over the counter and in October 2012 the company raised around $138 million on the New York Stock Exchange.